Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from BICO Group AB Class B ( (SE:BICO) ).
BICO reported a sharp downturn for 2025, with full-year net sales falling 13.3%, organic sales down 7.9%, and EBITDA turning negative, weighed by project delays in lab automation, soft demand from U.S. academia, and significant non-cash impairments in Discover ECHO and Biosero. Despite this, the group strengthened its balance sheet through divestments of MatTek and Visikol, bond buy-backs, and a new EUR 40m bond issue, while highlighting double-digit Q4 organic growth in Lab Automation, a resilient Life Science Solutions segment, and the launch of its GoSimple lab automation platform as it positions for a market recovery under continued macroeconomic uncertainty.
The most recent analyst rating on (SE:BICO) stock is a Hold with a SEK18.00 price target. To see the full list of analyst forecasts on BICO Group AB Class B stock, see the SE:BICO Stock Forecast page.
More about BICO Group AB Class B
BICO Group AB is a life science technology company focused on lab automation and life science solutions. Its portfolio includes automation-ready workcells and related technologies aimed at improving laboratory workflows for customers such as academic institutions and biopharma, with a strategic emphasis on selected high-value workflows.
Average Trading Volume: 192,664
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.23B
See more data about BICO stock on TipRanks’ Stock Analysis page.